“The Year of Ozempic” proclaimed the December 2023 edition of The New Yorker. That same month, the journal Science declared glucagon-like peptide-1 (GLP-1) weight loss drugs its “Breakthrough of the Year,” beating out commendable contenders such as new malaria and Alzheimer’s treatments, innovativ
